Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Zoe Boyer‐Díaz, Jordi Gracia‐Sancho(Institut d'Investigacions Biomèdiques de Barcelona), Anabel Fernández‐Iglesias(Hospital Clínic de Barcelona), Jean-Louis Junien(Inventiva (France)), Guillaume Wettstein(Inventiva (France)), Martí Ortega‐Ribera(Beth Israel Deaconess Medical Center), Peio Aristu-Zabalza(Departament de Salut), Claude Robert(Inventiva (France)), María Andrés‐Rozas, Pierre Broqua(Inventiva (France)), Jaime Bosch(University Hospital of Bern)
Cited by 163
Related Papers
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
|Clinical Nutrition|2024|44
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical
|Nutrients|2020|26